Crinetics Pharmaceuticals announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) for paltusotine to treat acromegaly. The EMA also granted paltusotine Orphan Drug Designation, highlighting the unmet need for acromegaly treatments. This follows the FDA’s acceptance of the New Drug Application (NDA) for paltusotine in the US, with a target action date of September 25, 2025.
This MAA validation is a crucial step towards expanding treatment access for acromegaly patients in Europe. The oral, once-daily nature of paltusotine offers a significant advantage over current injectable treatments, which can be burdensome and require frequent adjustments. Positive results from Phase 3 trials, demonstrating paltusotine’s efficacy and tolerability, further reinforce its potential to improve patient care and quality of life. The Orphan Drug Designation provides Crinetics with significant incentives, including reduced fees and potential market exclusivity, strengthening their competitive position in the European market.
The MAA is backed by data from 18 clinical trials, including two Phase 3 studies showing paltusotine’s effectiveness in both previously treated and untreated acromegaly patients. All primary and secondary endpoints were met in these trials, with paltusotine demonstrating statistically significant improvements in biochemical control (IGF-1 levels) and symptom control compared to placebo. The Orphan Drug Designation from the EMA may offer Crinetics up to 10 years of market exclusivity.
This progress positions paltusotine as a potential game-changer in acromegaly treatment. A successful EMA review could lead to a new, convenient, and effective therapy for European patients, while also solidifying Crinetics’ position as a leader in endocrine disease therapeutics. The upcoming FDA decision later this year further adds to the anticipation surrounding this promising new drug.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
